Gilead Sciences Inc. (GILD) Putting Brakes on HIV Drug Prices
Gilead Sciences Inc. (GILD) is freezing prices on most AIDS/HIV drugs it sells to government drug-assistance programs, and limiting even patients with private insurance to payments of $50 per month. In response to AIDS patient advocacy groups, the Foster City, CA developer and manufacturer of some of the best-selling treatments to suppress the AIDS virus said it will suspend price increases on its antiretroviral drugs to government payers through 2010. The decision came in a letter from Gregg Alton, Gilead's senior vice president and general counsel, to the AIDS Healthcare Foundation in Los Angeles. Alton, who is also on the…